This post was contributed by a community member. The views expressed here are the author's own.

Business & Tech

Hazelwood-Based Covidien Spin-Off to Acquire CNS Therapeutics

Mallinckrodt announced it would acquire the drug company to boost its product pipeline on Monday.

Hazelwood-based Mallinckrodt confirmed Monday that it would purchase CNS Therapeutics, based in St. Paul, MN for $100 million. The deal will include the acquisition of all outstanding capital stock in CNS and is expected to close by the end of the year.

CNS is a privately-held company that has products in development that will treat neurological disorders and chronic pain, as well as one marketed product called Gablofen, which is reportedly selling well and generating profit.

Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.

Gablofen is prescribed to treat severe spasticity in patients with neurological disorders.

The company’s U.S. operations will remain based in Hazelwood, while its legal headquarters will be in Ireland. Mallinckrodt was founded as G. Mallinckrodt & Co. in St. Louis in 1867. The company was acquired by Tyco International in 2000, which spun off its Tyco Healthcare division as Covidien in 2007, the Post reported.

Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.

We’ve removed the ability to reply as we work to make improvements. Learn more here

The views expressed in this post are the author's own. Want to post on Patch?

More from Hazelwood